317 related articles for article (PubMed ID: 11158499)
1. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
[TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
3. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
5. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
6. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
[TBL] [Abstract][Full Text] [Related]
7. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
9. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
Rennels MB; Deloria MA; Pichichero ME; Losonsky GA; Englund JA; Meade BD; Anderson EL; Steinhoff MC; Edwards KM
Pediatrics; 2000 Jan; 105(1):e12. PubMed ID: 10617749
[TBL] [Abstract][Full Text] [Related]
10. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
[TBL] [Abstract][Full Text] [Related]
14. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Matheson AJ; Goa KL
Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
[TBL] [Abstract][Full Text] [Related]
16. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
Bartels I; Jüngert J; Lugauer S; Stehr K; Heininger U
Vaccine; 2001 Apr; 19(23-24):3137-45. PubMed ID: 11312009
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
